Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivaroxaban 20 mg (Dexa Medica) vs Xarelto in Healthy Fed Subjects
NCT06558045Phase 1Completed
- Sponsor
- Dexa Medica
- Start
- Jul 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE), Atrial fibrillation (AFib), deep vein thrombosis (DVT) and 1 more (2 arms), sponsored by Dexa Medica. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 36 hours and Maximum plasma concentration at 36 hours. Started Jul 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT06558045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558045.